These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 12428725)

  • 1. Synergistic effects of pesticides and metals on the fibrillation of alpha-synuclein: implications for Parkinson's disease.
    Uversky VN; Li J; Bower K; Fink AL
    Neurotoxicology; 2002 Oct; 23(4-5):527-36. PubMed ID: 12428725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: a possible factor in Parkinson's disease.
    Uversky VN; Li J; Fink AL
    FEBS Lett; 2001 Jul; 500(3):105-8. PubMed ID: 11445065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.
    Uversky VN; Li J; Fink AL
    J Biol Chem; 2001 Nov; 276(47):44284-96. PubMed ID: 11553618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human alpha-synuclein.
    Li J; Uversky VN; Fink AL
    Biochemistry; 2001 Sep; 40(38):11604-13. PubMed ID: 11560511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid.
    Conway KA; Harper JD; Lansbury PT
    Biochemistry; 2000 Mar; 39(10):2552-63. PubMed ID: 10704204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy.
    Spillantini MG; Goedert M
    Ann N Y Acad Sci; 2000; 920():16-27. PubMed ID: 11193145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Forcing nonamyloidogenic beta-synuclein to fibrillate.
    Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
    Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes.
    Munishkina LA; Phelan C; Uversky VN; Fink AL
    Biochemistry; 2003 Mar; 42(9):2720-30. PubMed ID: 12614167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence for a partially folded intermediate in alpha-synuclein fibril formation.
    Uversky VN; Li J; Fink AL
    J Biol Chem; 2001 Apr; 276(14):10737-44. PubMed ID: 11152691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins.
    Uversky VN; Li J; Souillac P; Millett IS; Doniach S; Jakes R; Goedert M; Fink AL
    J Biol Chem; 2002 Apr; 277(14):11970-8. PubMed ID: 11812782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformational behavior of human alpha-synuclein is modulated by familial Parkinson's disease point mutations A30P and A53T.
    Li J; Uversky VN; Fink AL
    Neurotoxicology; 2002 Oct; 23(4-5):553-67. PubMed ID: 12428728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson's disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity.
    Irizarry MC; Growdon W; Gomez-Isla T; Newell K; George JM; Clayton DF; Hyman BT
    J Neuropathol Exp Neurol; 1998 Apr; 57(4):334-7. PubMed ID: 9600226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha-synuclein and the pathogenesis of Parkinson's disease.
    Martin FL; Williamson SJ; Paleologou KE; Allsop D; El-Agnaf OM
    Protein Pept Lett; 2004 Jun; 11(3):229-37. PubMed ID: 15182224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Α-synuclein misfolding and Parkinson's disease.
    Breydo L; Wu JW; Uversky VN
    Biochim Biophys Acta; 2012 Feb; 1822(2):261-85. PubMed ID: 22024360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
    Narhi L; Wood SJ; Steavenson S; Jiang Y; Wu GM; Anafi D; Kaufman SA; Martin F; Sitney K; Denis P; Louis JC; Wypych J; Biere AL; Citron M
    J Biol Chem; 1999 Apr; 274(14):9843-6. PubMed ID: 10092675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.
    Uversky VN; Eliezer D
    Curr Protein Pept Sci; 2009 Oct; 10(5):483-99. PubMed ID: 19538146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.
    Biere AL; Wood SJ; Wypych J; Steavenson S; Jiang Y; Anafi D; Jacobsen FW; Jarosinski MA; Wu GM; Louis JC; Martin F; Narhi LO; Citron M
    J Biol Chem; 2000 Nov; 275(44):34574-9. PubMed ID: 10942772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.
    Galvin JE; Uryu K; Lee VM; Trojanowski JQ
    Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13450-5. PubMed ID: 10557341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
    Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
    Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry.
    Braak H; Sandmann-Keil D; Gai W; Braak E
    Neurosci Lett; 1999 Apr; 265(1):67-9. PubMed ID: 10327208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.